International journal of urology : official journal of the Japanese Urological Association · 2026
Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matsushita Yuto, Kita Yuki, Mukai Shoichioro, Joraku Akira, Kobayashi Ikuo, Daizumoto Kei, Sano Tomoyasu, Nakanishi Shotaro, Watanabe Jun, Hatakeyama Shingo, Goriki Akihiro, Hazama Tatsuya, Nishiyama Naotaka, Mori Keiichiro, Kitamura Hiroshi, Kimura Takahiro, Matsui Yoshiyuki, Miyake Makito, Kobayashi Takashi, Inamoto Teruo, Japanese Urological Oncology Group
Аннотация
OBJECTIVES: Avelumab maintenance therapy following platinum-based chemotherapy is recommended as an alternative treatment in patients with locally advanced or metastatic urothelial carcinoma; however, real-world data are limited, and no predictive system has been established to identify suitable candidates for avelumab at the initiation of chemotherapy.
METHODS: This retrospective study analyzed 324 patients with locally advanced or metastatic urothelial carcinoma who received platinum-based chemotherapy. Patients were divided into three groups: 130 who received avelumab (avelumab group), 58 who did not experience disease progression on chemotherapy within 4 cycles but did not receive avelumab (PBC-only group), and 136 who experienced disease progression on chemotherapy within 4 cycles (PBC-PD group). Oncological outcomes were compared among the groups, and a system for predicting the maintained response to chemotherapy for 4 or more cycles was explored.
RESULTS: The avelumab group had significantly longer overall survival than the other two groups. After propensity score matching, overall survival was significantly longer in the avelumab group than in the PBC-only group. Lymph node-only metastasis and a low neutrophil-to-lymphocyte ratio were identified as predictive factors for maintaining response to chemotherapy. Among patients with these two factors (favorable group), 81.1% maintained a response, and those who received avelumab maintenance therapy showed that the median overall survival was 33.4 months from initiation of chemotherapy.
CONCLUSIONS: The survival benefit of avelumab following chemotherapy compared to chemotherapy alone was confirmed. In the favorable group, avelumab following chemotherapy may be a valuable option if they are ineligible or unwilling to receive the preferred regimen.
METHODS: This retrospective study analyzed 324 patients with locally advanced or metastatic urothelial carcinoma who received platinum-based chemotherapy. Patients were divided into three groups: 130 who received avelumab (avelumab group), 58 who did not experience disease progression on chemotherapy within 4 cycles but did not receive avelumab (PBC-only group), and 136 who experienced disease progression on chemotherapy within 4 cycles (PBC-PD group). Oncological outcomes were compared among the groups, and a system for predicting the maintained response to chemotherapy for 4 or more cycles was explored.
RESULTS: The avelumab group had significantly longer overall survival than the other two groups. After propensity score matching, overall survival was significantly longer in the avelumab group than in the PBC-only group. Lymph node-only metastasis and a low neutrophil-to-lymphocyte ratio were identified as predictive factors for maintaining response to chemotherapy. Among patients with these two factors (favorable group), 81.1% maintained a response, and those who received avelumab maintenance therapy showed that the median overall survival was 33.4 months from initiation of chemotherapy.
CONCLUSIONS: The survival benefit of avelumab following chemotherapy compared to chemotherapy alone was confirmed. In the favorable group, avelumab following chemotherapy may be a valuable option if they are ineligible or unwilling to receive the preferred regimen.
Предметные рубрики MeSH
HumansRetrospective StudiesFemaleAntibodies, Monoclonal, HumanizedMalePropensity ScoreMaintenance ChemotherapyPrognosisAgedMiddle AgedCarcinoma, Transitional CellAntineoplastic Combined Chemotherapy ProtocolsUrinary Bladder NeoplasmsDisease ProgressionTreatment OutcomeCisplatinAntineoplastic Agents, ImmunologicalLymphatic Metastasis